Navigation Links
Brupbacher Prize goes to cancer researcher Michael Karin
Date:1/29/2013

Molecular biologist Michael Karin is to receive this year's Charles Rodolphe Brupbacher Prize for Cancer Research in recognition of his studies on the role of chronic inflammation in the development of tumors. The award, which carries CHF 100,000 in prize money, is considered one of the highest accolades for cancer researchers worldwide. The awards ceremony takes place in Zurich this Thursday in the framework of an international symposium on "Breakthroughs in Cancer Research and Therapy".

On Thursday, 31 January 2013, the Charles Rodolphe Brupbacher Prize will be awarded for the 11th time to a scientist for outstanding achievements in cancer research. This year's award goes to Michael Karin, professor in the Department of Pharmacology at the University of California in San Diego.

Michael Karin is one of the most cited authors in biomedical science. He made a name for himself with his fundamental studies on the role of chronic inflammation in tumor development, such as hepatic cancer following an infection with the hepatitis B or C viruses or stomach cancer through an infection with the gastric bacterium Helicobacter pylori. A specific viral or bacterial pathogen, however, is not necessary because any chronic inflammatory damage to the intestinal mucosa carries a significantly increased risk of colon cancer. This includes immunologically induced inflammatory bowel diseases.

Evidence of causal link between inflammation and carcinogenesis

Karin is an internationally renowned expert on signaling pathways, transduction pathways that enable cells to respond to external influences. Karin is particularly interested in the influence of stress and infections. He showed how the cell's normal signaling pathways can go awry in the event of chronic infections, with cancer as a possible consequence.

Michael Karin's work has greatly advanced our understanding of the molecular basis of tumour development and is of vital importance in devising new strategies for prevention and therapy.

Public lecture by Gottfried Schatz and prizes for young scientists

On the eve of the award ceremony, the Brupbacher Foundation is holding a public lecture by Professor Gottfried Schatz entitled "Die tragische Substanz. Wie genetische Fehler Alterung und Krebs bewirken". Schatz is emeritus professor of the University of Basel and a biochemist of international standing especially in the field of mitochondria, the energy-providing powerhouses in the cell.

The last item on the symposium's program is devoted to young scientists: Up to five junior researchers will receive a Young Investigator Award at the conclusion of the symposium on Friday morning.


'/>"/>

Contact: Paul Kleihues
office@brupbacher-foundation.org
41-797-383-472
University of Zurich
Source:Eurekalert

Related biology news :

1. Brandeis scientists win prestigious prize for circadian rhythms research
2. Stanford and MIT scientists win Perl-UNC Neuroscience prize
3. March of Dimes awards $250,000 prize to 2 scientists who pioneered advances in skin disorders
4. The Brain Prize 2012 is presented May 9th
5. UCSF pair win Gruber Foundation Neuroscience prize
6. Mason environmentalist awarded Blue Planet Prize for lifetime achievement in conservation
7. Reaxys announces winners of the 2012 Reaxys Ph.D. Prize
8. $500,000 Gruber Foundation Genetics Prize goes to Philadelphia scientist
9. Dr. Douglas Wallace to receive Gruber Foundation 2012 Genetics Prize
10. University of Tennessee professor wins worlds top prize for ecology, environmental science
11. World Food Prize winner among speakers at agronomy, crop and soil science societies meetings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/13/2016)...  IMPOWER physicians supporting Medicaid patients in ... standard in telehealth thanks to a new partnership with ... IMPOWER patients can routinely track key health measurements, such ... and, when they opt in, share them with IMPOWER ... local retail location at no cost. By leveraging this ...
(Date:3/31/2016)...  Genomics firm Nabsys has completed a financial  restructuring ... , M.D., who returned to the company in October ... team, including Chief Technology Officer, John Oliver , ... and Vice President of Software and Informatics, Michael ... Dr. Bready served as CEO of Nabsys from 2005-2014 ...
(Date:3/23/2016)... 23, 2016 ... Gesichts- und Stimmerkennung mit Passwörtern     ... MESG ), ein führender Anbieter digitaler ... mit SpeechPro zusammenarbeitet, um erstmals dessen Biometrietechnologie ... die Möglichkeit angeboten, im Rahmen mobiler Apps ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... ... 2016 , ... While the majority of commercial spectrophotometers and fluorometers use the ... models are higher end machines that use the more unconventional z-dimension of 20mm. ... the bottom of the cuvette holder. , FireflySci has developed several Agilent flow ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge ... envision new ways to harness living systems and biotechnology, ... Art (MoMA) in New York City ... 130 participating students, showcased projects at MoMA,s Celeste Bartos ... Paola Antonelli , MoMA,s senior curator of architecture and ...
(Date:6/23/2016)... , June 23, 2016 Apellis ... Phase 1 clinical trials of its complement C3 ... single and multiple ascending dose studies designed to ... (PD) of subcutaneous injection in healthy adult volunteers. ... (SC) either as a single dose (ranging from ...
Breaking Biology Technology: